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DOI 10.1016/j.ccr.2010.11.024SUMMARYDiffuse large B cell lymphoma (DLBCL) comprises disease entities with distinct genetic profiles, including
germinal center B cell (GCB)-like and activated B cell (ABC)-like DLBCLs. Major differences between these
two subtypes include genetic aberrations leading to constitutive NF-kB activation and interference with
terminal B cell differentiation through BLIMP1 inactivation, observed in ABC- but not GCB-DLBCL. Using
conditional gain-of-function and/or loss-of-function mutagenesis in the mouse, we show that constitutive
activation of the canonical NF-kB pathway cooperates with disruption of BLIMP1 in the development
of a lymphoma that resembles human ABC-DLBCL. Our work suggests that both NF-kB signaling, as an
oncogenic event, and BLIMP1, as a tumor suppressor, play causal roles in the pathogenesis of ABC-DLBCL.INTRODUCTION
Diffuse large B cell lymphoma (DLBCL) is the most frequent
lymphoid malignancy, representing 30%–40% of all non-Hodgkin
lymphomas (Lenz and Staudt, 2010; WHO, 2008). DLBCL
comprises disease entities with distinct gene expression signa-
tures and response to therapy. Indeed, studies using geneexpres-
sionprofilinghaveclassifiedvarioussubtypesofDLBCLaccording
to their putativecell oforigin (COO)orconsensusclusters (Alizadeh
et al., 2000;Monti et al., 2005). In the COOclassification, twomain
subgroups of DLBCL emerged. One is the germinal center B cell
(GCB)-like DLBCL, which has a gene expression profile that
closely resembles that of normal germinal center (GC) B cells.
Theother is activatedBcell (ABC)-likeDLBCL,withageneexpres-
sion profile resembling that of in vitro ABCs (Alizadeh et al., 2000).Significance
ABC-DLBCL is themost aggressive DLBCL and has a poor clin
apoptotic effect of chemotherapy and may account for the po
studies in the mouse improve the understanding of human ABC
rent events in this disease, constitutive NF-kB activity and a
disruption, cooperate in lymphomagenesis. Because of the si
with human ABC-DLBCL, these mice may serve as a preclinic
oncogenic events and new therapeutic targets.
580 Cancer Cell 18, 580–589, December 14, 2010 ª2010 Elsevier IncDLBCLs carry somatically mutated rearranged immunoglob-
ulin (Ig) V region genes (Lenz and Staudt, 2010; Lossos et al.,
2000). Although somatic hypermutation (SHM) of Ig genes may
not be entirely GC specific, the GCB-DLBCL gene expression
profile in conjunction with often ongoing SHM strongly suggests
that this lymphoma is indeed derived from a GC B cell. In the
case of ABC-DLBCL, the COO is less clearly defined and may
be either a late GC B cell, an activated post-GC, or even a GC
unrelated B cell (Lenz and Staudt, 2010).
A major difference between GCB-DLBCL and ABC-DLBCL is
constitutive NF-kB activity in the latter (Alizadeh et al., 2000;
Staudt, 2010). NF-kB signaling plays a crucial role in B cell phys-
iology and can make B cells independent of survival factors,
such as BAFF (Sasaki et al., 2006). Similarly, ABC- but not
GCB-DLBCL relies on constitutive activity of the canonicalical prognosis. Constitutive NF-kB activity interferes with the
or response to treatment of patients with ABC-DLBCL. Our
-DLBCL pathogenesis by the demonstration that two recur-
brogation of terminal B cell differentiation through BLIMP1
milarity of the lymphomas arising in the compound mutants
al model for this disease and be used to identify additional
.
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Recently, mutations leading to constitutive canonical NF-kB
activation in ABC-DLBCL have been described (Compagno
et al., 2009; Davis et al., 2010; Kato et al., 2009; Lenz et al.,
2008a). Another characteristic of ABC-DLBCL is genetic alter-
ations that interfere with terminal B cell differentiation. Thus,
25% of ABC-DLBCLs show inactivating mutations of BLIMP1
(Pasqualucci et al., 2006; Tam et al., 2006), a key regulator of
plasma cell differentiation (Martins and Calame, 2008), suggest-
ing that BLIMP1 may function as a tumor suppressor in the
pathogenesis of ABC-DLBCL. Additional recurrent mutations in
ABC-DLBCL that block plasma cell differentiation include
genetic aberrations resulting in deregulated expression of SPIB
(26%) or BCL6 (24%) (Iqbal et al., 2007; Lenz and Staudt,
2010; Lenz et al., 2008b).
In an attempt to assess the roles of NF-kB activation and
BLIMP1 disruption in the pathogenesis of ABC-DLBCL, we used
a genetic system in the mouse that allows conditional gain-of-
function and/or loss-of-function mutagenesis in GC B cells.
RESULTS
Experimental Design
For targeted mutagenesis in GC B cells, we used the Cg1-cre
transgene, expressed in B cells at early stages of theGC reaction
(Casola et al., 2006). To induce activation of the NF-kB canonical
pathway, we combined this transgene with a ROSA26 allele,
termed IKK2castopFL, that harbors a cDNA encoding a constitu-
tively active IKK2 protein, which mediates canonical but not
alternative NF-kB activation, preceded by a loxP flanked STOP
cassette (Sasaki et al., 2006). We complemented this system by
introducing a conditional BLIMP1 allele (Blimp1F; Ohinata et al.
[2005]), alone or in combination with IKK2castopFL. Activation of
the IKK2castopFL allele by Cre-mediated recombination ismarked
by expression of GFP under the control of an internal ribosomal
entry site downstream of the inserted IKK2ca cDNA. To report
Cre-mediated recombination in cells carrying the Blimp1F allele,
we combined it with a ROSA26 reporter allele harboring an YFP
gene preceded by a loxP flanked STOP cassette (eYFPstopFL;
Srinivas et al. [2001]). Mice carrying the Cg1-cre transgene in
combination with eYFPstopFL served as controls.
Impact of NF-kB Activation and BLIMP1 Deletion on the
GCReaction andBCell Proliferation andSurvival In Vitro
To determine the impact of enforced NF-kB activation and/or
disruption of BLIMP1 on the GC reaction, we examined splenic
GC B cells in control and experimental mice upon immunization
with sheep red blood cells (SRBCs). Mice with BLIMP1 deletion
alone showed increased numbers of GC B cells at day 10 after
primary immunization (Figures 1A and 1C), a trend that persisted
to day 21 and upon secondary immunization (Figures 1B and 1C).
In contrast, mice with enforced expression of IKK2ca alone
showed some reduction in the GC B cell fraction at day 10 after
primary (Figures 1A and 1C) and secondary immunization (Fig-
ure 1C), to which the increased BLIMP1 levels in these cells
may contribute (Figure 1D) (Martins and Calame, 2008). Indeed,
concomitant BLIMP1 disruption overrode this effect and, like
deletion ofBLIMP1 alone, led to increased numbers of GCBcells
(Figures 1A and 1C). However, 21 days after primary immuniza-Cantion, the spleens of mice with enforced NF-kB activation alone
or together with BLIMP1 loss were virtually devoid of GFPpos
GC B cells (Figures 1B and 1C). Although constitutive NF-kB
activation did not affect AICDA transcript levels in GC B cells
10 days after immunization, the few remainingGCBcells in these
mice on day 21 post-immunization carried a significantly lower
number of somatic mutations in their Ig heavy chain (IgH) V
regions compared to controls (Figures 1E and 1F). Collectively,
these results suggest that constitutive NF-kB activity promotes
premature termination of the GC reaction through both
BLIMP1-dependent and -independent mechanisms, thereby
reducing the load of somatic mutations in the GC progeny.
With respect to cell proliferation, BLIMP1 deletion in GC B
cells, with or without concomitant activation of NF-kB, resulted
in a small, but significant increase of the fraction of cells in the
S and G2 phases of the cell cycle, compared to controls (Fig-
ure 2A). This could be due to the loss of BLIMP1 (Figure 1D),
which is thought to repress genes promoting cell cycle progres-
sion, in the small fraction (0.5%–4%) of BLIMP1pos GC B cells
(Angelin-Duclos et al., 2000; Lin et al., 1997;Martins andCalame,
2008). In accord with the notion of an antiproliferative effect of
BLIMP1, its acute ablation also promoted the proliferation of B
cells in an in vitro cell culture system that mimics T cell-depen-
dent B cell activation (Figures 2B–2D). In this in vitro cell culture
system, the efficiency of Cre-mediated recombination was iden-
tical in B cells from mice of the various genotypes and virtually
complete by day 3 of culture, as measured by the expression
of the reporter genes (Figure 2B).
Interestingly, enforced IKK2ca expression in the in vitro
system not only inhibited apoptosis of the ABCs (Figure 2E)
but also enhanced their proliferation and cooperated with
BLIMP1 loss in accumulating increased numbers of cells over
the 5-day culture period (Figures 2C and 2F). These results
contrast with both the absence of an effect of enforced IKK2ca
expression on the cell cycle distribution of GC B cells in vivo
(Figure 2A) and the IKK2ca-mediated premature termination of
the GC reaction (Figure 1). We considered the possibility that
constitutive NF-kB signaling in GC B cells might interfere with
BCL6 expression (Saito et al., 2007) but could not detect such
an effect when we analyzed BCL6 mRNA expression by quanti-
tative PCR (data not shown).
Ablation of BLIMP1 Precludes Plasma Cell Formation
Asexpected from the literature (Martins andCalame, 2008), abla-
tion of BLIMP1 in B cells through Cg1-cre severely impeded
plasma cell formation in both Cg1-cre;Blimp1FFeYFPstopFL and
Cg1-cre;Blimp1FFIKK2castopFL mice, 10 days after primary and
secondary immunization (Figures 3A and 3B; see Figures S1A
and S1B, available online), accompanied by a strong reduction
of total as well as SRBC-specific IgG1, but not IgM, antibodies
in the sera of the animals (Figure 3C; FigureS1C; data not shown).
Thus, in agreement with BLIMP1’s essential role in terminal B cell
differentiation, its inactivation in our experimental system blocks
plasma cell differentiation, also when combined with constitutive
NF-kB activation. In contrast, activation of NF-kB alone was
compatible with plasma cell differentiation (Figures 3A and 3B;
Figures S1A, and S1B), and antibody titers in the sera of Cg1-
cre;IKK2castopFL mice 10 days after primary immunization were
similar to those in control mice (Figure 3C; Figure S1C).cer Cell 18, 580–589, December 14, 2010 ª2010 Elsevier Inc. 581
Figure 1. Impact of Constitutive NF-kB Activation and BLIMP1 Deletion on the GC Reaction
(A) Left panel shows analysis by flow cytometry of the GC B cell population (CD19posB220PosCD38LowFasHigh) in spleen 10 days after primary immunization with
SRBCs of at least three mice per genotype. Right panel demonstrates reporter expression in GC B cells.
(B) Analysis of GC B cells as in (A) 21 days after primary immunization with SRBCs of at least three mice per genotype.
(C) Number of reporter-positive GC B cells in spleen at days 10 (1 day 10) and 21 (1 day 21) after primary immunization and of mice re-immunized 30 days after
primary immunization and analyzed 10 days thereafter (2 day 10). Red bar represents mean of at least three mice per genotype.
(D) Relative BLIMP1 transcript levels in reporter-positive GC B cells at day 10 after primary immunization. Values represent normalized levels to HPRT, relative to
control (Cg1-cre;eYFPstopFL). Data are represented as mean ± SEM of three mice per genotype. Numbers in graph represent mean value.
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Figure 2. B Cell Proliferation and Survival upon BLIMP1 Deletion and Constitutive NF-kB Activation
(A) DNA content of reporter-positive GC B cells at day 10 after primary immunization was determined using the Draq5 DNA-binding reagent and flow cytometry.
Data are represented as mean ± SEM of four mice per genotype.
(B) Cre-mediated recombination efficiencymeasured by expression of reporter genes in purified B cells from compoundmutant mice and control, cultured in vitro
in the presence of aCD40 plus IL4. Data are representative of three independent experiments.
(C) CFSE dilution profile of in vitro cultured splenic B cells 5 days after stimulation with aCD40 plus IL4 from mice of the indicated genotypes. Data are represen-
tative of three independent experiments.
(D) Relative BLIMP1 transcript levels in in vitro cultured splenic B cells 4 days after stimulation with aCD40 plus IL4 frommice of the indicated genotypes. Values
represent normalized levels to HPRT, relative to control (Cg1-cre;eYFPstopFL). Data are represented as mean ± SEM of three independent experiments. Numbers
in graph represent mean values.
(E) Frequency of apoptotic cells within in vitro-cultured splenic B cells 5 days after stimulation with aCD40 plus IL4 frommice of the indicated genotypes. Data are
represented as mean ± SEM of three independent experiments.
(F) Percent (%) live cells relative to input in in vitro-cultured splenic B cells at days 3, 4, and 5 after stimulation with aCD40 plus IL4 from mice of the indicated
genotypes. Percent (%) live cells relative to input is calculated based on the cell number of live cells at days 3, 4, and 5 relative to the cell number of live cells at day
0. Data are represented as mean ± SEM of three independent experiments.
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BLIMP1 and IKK2ca Mutation
To assess the role of constitutive activation of the canonical
NF-kB pathway and/or disruption of BLIMP1 in lymphomagene-(E) IgH somatic mutation in reporter-positive GC B cells at day 10 (eight or more
more sequences per mouse from at least three mice per genotype) after prim
frequency at day 21 is given in red.
(F) Relative AICDA transcript levels in reporter-positive GC B cells at day 10 after
control (Cg1-cre;eYFPstopFL). Data are represented as mean ± SEM of three mic
Cansis, we generated cohorts of compound mutant mice and moni-
tored them for tumor formation over a period of 550 days. Mice
with enforced expression of IKK2ca alone showed a similar life
span as control mice (Figure 4). In contrast, deletion of BLIMP1sequences per mouse from at least two mice per genotype) and day 21 (ten or
ary immunization with SRBCs. Red bar represents mean. Average mutation
primary immunization. Values represent normalized levels to HPRT, relative to
e per genotype. Numbers in graph represent mean value.
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Figure 3. BLIMP1 Inactivation Dominantly
Abrogates Plasma Cell Formation
(A) Left panel shows flow-cytometric analysis of
splenic plasma cells (B220LowCD138Pos) at day
10 after primary immunization of at least three
mice per genotype. Right panel demonstrates
frequency of reporter-positive plasma cells.
(B) Reporter-positive plasma cell numbers in
spleen at day 10 after primary immunization and
secondary immunization. Red bar represents
mean of at least three mice per genotype.
(C) SRBC-specific IgG1 serum antibodies at day
10 after primary immunization. Data are repre-
sented as mean ± SEM of three mice per geno-
type. Low ctrl, unimmunizedmice; High ctrl, serum
from mice hyperimmunized with SRBCs. See also
Figure S1.
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further enhanced by the constitutive activation of the canonical
NF-kB pathway (Figure 4).
Plasma Cell Hyperplasia in Mice with Constitutive
Canonical NF-kB Activation
Macroscopic examination of Cg1-cre;IKK2castopFL mice, sacri-
ficed between 550 and 600 days of age, revealed the presence
of enlarged spleens in all cases (six of six), with a significant
hyperplasia of both B and plasma cells in spleen and bone
marrow (Figures 5A and 5B; Figures S2A and S2B). Accordingly,
large numbers of cells expressing intracellular Ig and the plasma
cell marker CD138 could be detected in splenic histological
sections of thesemice, whereas there was essentially no expres-
sion of the GC B cell marker PNA (Figure 5C; data not shown).
Consistent with the increased numbers of plasma cells, the
serum titers of both IgM and IgG1 were higher in Cg1-cre;
IKK2castopFL mice than controls (Figure S2C). Electrophoretic
analysis of sera from these mice revealed the presence of
distinct band(s) in the g-globulin region of the gel (M-spikes) in
70% of Cg1-cre;IKK2castopFL mice (seven of ten) compared to584 Cancer Cell 18, 580–589, December 14, 2010 ª2010 Elsevier Inc.20% (two of ten) of controls, indicative
of clonal or oligoclonal plasma cell
expansions (Figure 5D; data not shown).
Thus, constitutive activation of the NF-
kB canonical pathway promotes not
only B cell hyperplasia, consistent with
our previous results (Sasaki et al., 2006),
but also plasma cell hyperplasia.
BCell-Specific BLIMP1 Inactivation
Leads to B Cell Lymphomagenesis
Examination of terminally ill Cg1-cre;
Blimp1FFeYFPstopFL mice revealed
splenomegaly in all cases (11/11), occa-
sionally together with lymphadenopathy,
and hepatomegaly in one case (Fig-
ure 6A; data not shown). Histological
analysis of enlarged spleens and lymph
nodes showed in six of seven mice
examined the presence of large cellswith a diffuse growth pattern, resembling human DLBCL (Fig-
ure 6B). These cells were immunohistochemically negative for
CD138 and intracellular Ig but expressed the B cell marker
CD19 and, thus, represented transformed B rather than plasma
cells (Figure 6C; data not shown). The analysis of IgH gene
rearrangements by Southern blot in spleen and lymph nodes
revealed that the lymphoproliferations were of clonal origin in
six of eight cases (Figure 6D). We succeeded in amplifying
IgH rearrangements from three clonal tumors by PCR and found
that two of them were highly somatically mutated, whereas the
third one carried a single nucleotide exchange (Table S1). We
then assessed whether these lymphomas resembled a partic-
ular DLBCL subtype. Expression of MUM1/IRF4 as identified
by immunohistochemical staining correlates with ABC-,
whereas BCL6 expression is primarily associated with GCB-
DLBCL (Choi et al., 2009; Hans et al., 2004), although a fraction
of ABC-DLBCLs is also positive for BCL6 (Alizadeh et al., 2000;
Iqbal et al., 2007; Lenz and Staudt, 2010). Consistent with an
ABC-DLBCL phenotype, five of six DLBCLs arising in Cg1-cre;
Blimp1FFeYFPstopFL mice were IRF4posBCL6neg by immuno-
histochemical staining, whereas the remaining case was
Figure 4. Survival of Mice Carrying the Cg1-cre Transgene Together
with Blimp1F, IKK2castopFL, or Both Alleles
Kaplan-Meier survival graph of mice of the indicated genotypes. Med. surv,
median survival; und, undefined.
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PNA (Figure 6E; Figures S3A and S3B). Because IRF4 is a target
of the NF-kB pathway (Grumont and Gerondakis, 2000; Saito
et al., 2007), and most human ABC-DLBCLs show NF-kB
activation, we looked at whether this pathway was activated
in lymphomas arising upon BLIMP1 loss. Using the YFP
reporter as a marker, we purified lymphoma cells from the
IRF4negBCL6pos (L1) and two IRF4posBCL6neg (L2, L3)
lymphomas, for which we had material available, and deter-
mined the transcript levels of known NF-kB target genes
frequently expressed in human ABC-DLBCL (Alizadeh et al.,
2000). Consistent with a GCB-DLBCL phenotype, the L1
lymphoma had low expression of NF-kB target genes and
elevated transcript levels of GC B cell markers (Figure 6F). In
contrast the L2 and L3 lymphomas showed elevated expression
of some (NFKBIA, PIM2, BCL2) or all NF-kB target genes tested
but low transcript levels of GC B cell markers (Figure 6F). We
searched for mutations of the A20, CARD11, and CD79a and
b genes in these cells, which have been associated with consti-
tutive NF-kB activation in human ABC-DLBCL. However, no
such mutations were detected by sequence analysis of
amplified cDNAs. We also tested the expression levels of
non-NF-kB target genes typically expressed in human ABC-
DLBCL (Wright et al., 2003), including the transcription factor
FOXP1, indicative of a poor clinical prognosis (Banham et al.,
2005; Lenz and Staudt, 2010). Both L2 and L3 had elevated
levels of FOXP1 compared to GC B cells; however, only L3
showed expression of the majority of the other ABC-DLBCL
associated genes tested (Figure 6F). Together, our results
demonstrate that BLIMP1 inactivation promotes lymphoma
development in the mouse, in agreement with the recent results
of others (Mandelbaum et al., 2010 [this issue of Cancer Cell]).
In addition the lymphomas arising in these mice often show
molecular features of human ABC-DLBCL.
Synergy between NF-kB Activity and BLIMP1 Loss
in B Cell Lymphomagenesis
Mice with combined BLIMP1 deletion and activation of the
NF-kB pathway had a significantly reduced life span comparedCanto mice with BLIMP1 inactivation alone (Figure 4). Similar to
the latter, these mice succumbed to a B cell-derived lymphopro-
liferative disease affecting spleen and lymph nodes, showing in
all five cases analyzed morphological features resembling
human DLBCL (Figures 6A–6C; data not shown). Analysis of
IgH rearrangements by Southern blot showed that these mice
develop clonal lymphomas (Figure 6D). Sequence analysis of
the clonal IgH rearrangements amplified by PCR revealed the
presence of several somatic point mutations in one case and
a single nucleotide exchange in another, whereas no mutations
could be detected in two other cases. These latter tumors, like
the one with a single mutation, expressed IgM on their surface
(Table S1). Consistent with an ABC-DLBCL phenotype and
constitutive NF-kB activation, five of five lymphomas analyzed
were IRF4posBCL6neg by immunohistochemical staining (Fig-
ure 6E; Figure S3A). Analysis of purified (GFPpos) tumor cells
from three of these lymphomas for which we had material
available (L4, L5, L6) revealed low expression of GC B cell
markers and elevated transcript levels for most of the ABC-
DLBCL associated NF-kB target and nontarget genes tested,
compared to GC B cells (Figure 6F). Collectively, these results
reveal a strong cooperative effect between constitutive activa-
tion of the canonical NF-kB pathway and BLIMP1 loss in the
pathogenesis of lymphomas resembling human ABC-DLBCL.
DISCUSSION
Using conditional mutagenesis in GC B cells in the mouse, we
show that BLIMP1 disruption promotes the development of
lymphomas often resembling human ABC-DLBCL. This is in full
accord with the results of Mandelbaum et al. (2010). The low
penetrance, long latency, and clonality of DLBCL in these mice
suggested that additional oncogenic events are required for
the pathogenesis of this disease. A major candidate for one
such event is the NF-kB pathway because the majority of human
ABC-DLBCLs display constitutive NF-kB activation, and most
lymphomas arising upon conditional BLIMP1 deletion in mice
also show activation of this pathway. Indeed, we found that
constitutive activation of the canonical NF-kB pathway strongly
synergized with loss of BLIMP1 in lymphomagenesis. Thus, our
work suggests that both NF-kB signaling and the loss of BLIMP1
play causal roles in the pathogenesis of human ABC-DLBCL.
Similar to ABC-DLBCL, genetic alterations leading to constitu-
tive NF-kB activation have been described in multiple myeloma,
suggesting a role for this pathway in the pathogenesis of this
disease (Annunziata et al., 2007; Keats et al., 2007; Staudt,
2010). Supporting this concept, we found that constitutive acti-
vation of NF-kB through the Cg1-cre transgene promotes
plasma cell hyperplasia. If ABC-DLBCLs indeed derive from an
ABC at an early stage of plasma cell differentiation (Lenz and
Staudt, 2010), these results in turn indicate that the pathogenesis
of this disease necessarily requires interference with terminal B
cell differentiation, as exemplified by BLIMP1 inactivation.
Besides abrogating B cell terminal differentiation, the loss of
BLIMP1may promote cellular proliferation through derepression
of BLIMP1 target genes controlling cell cycle progression (Lin
et al., 1997; Martins and Calame, 2008). Constitutive activation
of the canonical NF-kB pathway, on the other hand, releases
B cells from their dependence of extracellular survival signals,cer Cell 18, 580–589, December 14, 2010 ª2010 Elsevier Inc. 585
Figure 5. Constitutive Canonical NF-kB Signaling Promotes Plasma Cell Hyperplasia
(A) Representative picture of spleens fromR550-day-old mice of the indicated genotypes. Six mice per genotype were analyzed.
(B) Absolute number of reporter-positive plasma cells (CD19negCD138pos) in spleen and bonemarrow ofR550-day-old mice of the indicated genotypes. Red bar
represents mean of at least six mice per genotype.
(C) Representative immunohistochemical staining of spleens fromR550-day-oldmice of the indicated genotypes. Upper panel showsH&E,middle panel CD138,
and lower panel intracellular Ig. Six mice were analyzed per genotype. Scale bar, 1000 mm; inset, 100 mm.
(D) Representative serum protein electrophoresis of sera fromR550-day-old mice of the indicated genotypes. The position of albumin and of other components
of the serum is indicated. * indicates M-spike/s. At least ten mice per genotype were analyzed. See also Figure S2.
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enhances the proliferative response of mitogen-stimulated B
cells (Sasaki et al., 2006). Thus, the cooperative effect ofBLIMP1
disruption and constitutive NF-kB signaling in the pathogenesis
of human ABC-DLBCL likely results from blocking the differenti-
ation of an ABC that displays deregulated proliferative and
survival properties.
The increased and abnormally prolonged GC reaction in
Cg1-cre;Blimp1FFeYFPstopFL mice in conjunction with the pres-
ence of somatically mutated Ig gene rearrangements in the lym-
phomas arising upon BLIMP1 deletion suggests that the latter
likely originate predominantly from either a late or a post-GC B
cell. The situation is less clear in the case of BLIMP1 ablation
in combination with activation of the NF-kB pathway, where
we did not detect somatic mutations in the majority of the586 Cancer Cell 18, 580–589, December 14, 2010 ª2010 Elsevier Inctumors. It is possible that this reflects an inherent feature of
our experimental approach, in that NF-kB activation early on in
the GC reaction leads to its premature termination (Bolduc
et al., 2010; Kishi et al., 2010; and the present work). It may
become significant in this situation that the Cg1-cre transgene
induces Cre-mediated recombination also in a small fraction of
IgM-expressing non-GC B cells, whose absolute numbers easily
compare to those of GC B cells (Casola et al., 2006). Such cells
likely include antigen ABCs that have not yet entered the GC
reaction (Casola et al., 2006; Garside et al., 1998; Toellner
et al., 1996) and to whose proliferative expansion and ultimate
transformation Cre-mediated NF-kB activation and loss of
BLIMP1 would equally contribute, as in the case of B cells acti-
vated in the course of the GC reaction. Indeed, the lymphomas
arising in the compound mutants and carrying unmutated Ig.
Figure 6. Mice with BLIMP1 Deletion Alone
and in Combination with Constitutive
Canonical NF-kB Signaling Develop
Lymphoma with an ABC Phenotype
(A) Representative pictures of spleens of
compound mutant and control mice.
(B) Representative H&E staining of spleens of
compound mutant (with six Cg1-cre;Blimp1FF
eYFPstopFL and five Cg1-cre;Blimp1FFIKK2castopFL
mice analyzed) and control mice. Scale bar,
1000 mm; inset, 100 mm.
(C) Representative analysis of cell size and CD19
expression of reporter-positive tumor cells from six
Cg1-cre;Blimp1FFeYFPstopFL and five Cg1-cre;
Blimp1FFIKK2castopFLmice and control mice.
(D) Southern blot analysis for tumor clonality using
a JH4 probe. Clonal tumors usually exhibit two
bands corresponding to VDJ and DJ rearrange-
ments.
(E) Representative immunohistochemical staining
for MUM1/IRF4 of spleens of compound mutant
(with five Cg1-cre;Blimp1FFeYFPstopFL and five
Cg1-cre;Blimp1FFIKK2castopFL mice analyzed) and
control mice. Scale bar, 1000 mm; inset, 100 mm.
(F) Heatmap showing the relative transcript levels of
candidate genes in lymphoma samples compared
to GC B cells. For heat map generation the HPRT-
normalized value of each candidate gene was
normalized to have mean zero, variance one. See
also Figure S3 and Table S1.
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scenario the presentmousemodel reproduces the pathogenesis
of a B cell lymphoma originating from the transformation of an
ABC and, thus, of human ABC-DLBCL. However, in the latter
case the activated COO usually represents a B cell in which
the SHM mechanism is or has been operating because of its
increased risk to accumulate unwanted mutational events
(Lenz and Staudt, 2010). This feature applies less stringently in
our system of conditional mutagenesis.
The lymphomas arising upon disruption of BLIMP1 alone and
in combination with constitutive NF-kB activation in compound
mutantmice are of clonal origin, suggesting that additional onco-
genic event(s) occurred that led to the outgrowth of a particular
B cell clone. Because of the similarity of these lymphomas with
human ABC-DLBCL, the identification of these additional
genetic lesions might lead to the discovery of critical players in
ABC-DLBCL pathogenesis and open the way to new therapeutic
strategies.Cancer Cell 18, 580–589, DEXPERIMENTAL PROCEDURES
Mice, Immunization, and Tumor Cohorts
Cg1-cre, IKK2castopFL, Blimp1FF, and eYFPstopFL
alleles have been described (Casola et al., 2006;
Ohinata et al., 2005; Sasaki et al., 2006; Srinivas
et al., 2001). Eight- to 10-week-old mice were
immunized i.v. with 1 3 109 SRBCs (Cedarlane)
in PBS. Mouse cohorts were monitored twice
aweek for tumor development undermonthly anti-
genic stimulation by SRBC immunization and
euthanized if signs of tumor development
occurred. All animal care and proceduresfollowed National Institutes of Health guidelines and were approved by the
Institutional Animal Care and Use Committee (IACUC 03341) of Harvard
University and the Immune Disease Institute.
Flow Cytometry
Lymphoid single-cell suspensions were stained with the following monoclonal
antibodies from BD: aCD19(ID3), aB220(RA3-6B2), aCD95(Jo2), aCD138
(281-2), and aCD38(90). Samples were acquired on a FACSCanto II (BD) and
analyzed using FlowJo software (Tree Star, Inc.).
ELISA and SRBC-Specific Antibody Detection
ELISA was performed as described (Casola et al., 2006). For detection of
SRBC-specific IgG1, 2 3 106 SRBCs were incubated with sera for 20 min at
4C, washed twice with 1 3 PBS, and then incubated with amouseIgG1
(A85-1; BD) antibody for 20 min at 4C. After one wash with 1 3 PBS, the
geometric mean of the fluorescence intensity was determined through the
acquisition of SRBC samples by flow cytometry.
Serum Protein Electrophoresis
Serum was diluted 1:2 in barbital buffer and analyzed on a Hydragel K20
system according to manufacturer’s instruction (Sebia).ecember 14, 2010 ª2010 Elsevier Inc. 587
Cancer Cell
Modeling Activated B Cell-like DLBCL in the MouseReal-Time PCR and Heat Map Generation
Total RNA was extracted using TRIzol reagent, and cDNA was synthesized
using the ThermoScript RT-PCR System (Invitrogen). For qRT-PCR we used
Power SYBR Green, followed by analysis with the StepOnePlus System
(Applied Biosystems). Samples were assayed in duplicate, and messenger
abundance was normalized to that of HPRT. To detect BLIMP1 transcripts
we used a primer set pairing in the exon 4-5 junction. Because in the Blimp1F
allele exon 5 is loxp flanked and will be deleted upon Cre-mediated recombi-
nation (Ohinata et al., 2005), we used this primer set to confirm BLIMP1
deletion. Heat map was generated using the Matrix2png software (Pavlidis
and Noble, 2003).
Analysis of Tumor Clonality
This was done by Southern blotting of EcoRI-digested genomic DNA from
tumors using a JH probe spanning the JH4 exon and part of the downstream
intronic sequence.
Histology
Tissues were fixed with 10% formalin (Sigma), and paraffin-embedded
sections were stained with hematoxylin and eosin (H&E; Sigma), aIRF4
(MUM1; Santa Cruz), aBCL6 (sc-C19; Santa Cruz), PNA (Vector), aCD138
(281-2; BD), and amIg (Vector).
GC B Cell DNA Content Analysis
Cells were stained for surface markers and fixed with 2% formaldehyde for
15min at RT and then incubated with the DNA-binding agent Draq5 (Biostatus)
at a final concentration of 12.5 mM for 30 min at RT. Samples were acquired
and analyzed as above. Cell cycle analysis was performed using the
Watson-Pragmatic computational model in FlowJo software.
IgH Somatic Mutation Analysis
Genomic DNA was prepared from tumor tissues or sorted B cells. IgH-V gene
rearrangements were PCR amplified using the Expand High Fidelity PCR
System (Roche) and forward primers VHA and VHE (Ehlich et al., 1994), and a
reverse primer in the JH4 intron (5
0-CTCCACCAGACCTCTCTAGACAGC-30).
Fragments were cloned, sequenced, and blasted against the NCBI database
(http://www.ncbi.nlm.nih.gov/igblast/) to determineVHDHJHusage. The cloned
intronic sequences were then aligned to their germline counterparts. In deter-
mining somatic mutations we excluded polymorphisms associated with the
Cg1-cre allele.
In Vitro Cell Culture, CFSE Labeling, and Detection of Apoptotic
Cells
Splenic B cells were purified by CD43 depletion (Miltenyi). Cells were cultured
in the presence of 1 mg/ml aCD40 (HM40-3; eBioscience) and 25 ng/ml IL-4
(R&D Systems). To monitor cellular division, B cells were labeled in 1 ml
2.5 mM CFSE (Invitrogen) in 1 3 PBS per 107 cells at 37C for 10 min. Before
acquisition of CFSE-labeled cells by flow cytometry, inactivation of GFP or
YFP fluorescence was achieved by fixing cells using a Fix/Perm reagent
(eBioscience). Cells undergoing apoptosis were detected using the Active
Caspase-3 Apoptosis Kit (BD), according to manufacturer’s instructions.
Statistical Analysis
Data were analyzed using unpaired two-tailed Student’s t test; a p value%0.05
was considered significant. A single asterisk (*) in the graphs of figures
represents a p value %0.05, double asterisks (**) a p value%0.01, and triple
asterisks (***) a p value%0.001, and ‘‘ns’’ stands for not statistically significant,
i.e., a p value >0.05. Survival curves were compared using the log rank test.
Data in text and figures are represented as mean ± standard error of the
mean (SEM).
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